Clinical Trials
As an infrastructure at the German Center for Infection Research (DZIF), the Clinical Trial Unit tracks DZIF's study activities in the “Healex Site Management System (SMS)”. Studies are sorted by indication and are continuously updated.
The study register has recently been expanded to include the category “COVID-19”. For the first time, not only DZIF study activities are presented here: In order to provide a comprehensive overview in the current pandemic situation of planned and already active COVID-19 studies in Germany, the Clinical Trial Unit is cooperating with researchers from various German Centers for Health Research and other networks.
For researchers: If your study is not yet included in our portal, please contact the project management of the Clinical Trial Unit.
- Viral Infections
- COVID-19
- MERS-CoV
- Ebola
- Hepatitis
- HIV / AIDS
- CAPNETZ: CAPNETZ: Community Acquired Pneumonia NETZwerk
- Elvitegravir (EVG): A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL) Each Administered With a Background Regimen in HIV-1 Infected, Antiretroviral Treatment-Experienced Adults
- EUROSIDA: EUROSIDA Kohorte
- GSK1349572 Open label Protocol EAP: A GSK1349572 Open label Protocol for HIV infectected, Adult patients with Integrase Resistance
- GSK 201636:
- HIV-Kohorte:
- LATTE-2: A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects
- MK-1439-007: A Dose-Ranging Study to Compare MK-1439 Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
- New Era HIV Studie: A multicenter, open-label, non-randomized trial to evaluate treatment with multi-drug class (MDC) HAART and its impact on the decay rate of latently infected CD4+ T cells
- Protekt-Kohorte:
- Influenza
- Varizella zoster
- Bacterial Infections
- Infektionen bei Immungeschwächten Patienten
- Invasive Pilzinfektionen
- Gastrointestinale Infektionen